Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On Thursday a group of independent advisors recommended that the FDA authorize a third dose of Moderna's coronavirus vaccine for most people.

The FDA's expert panel just unanimously backed Moderna's booster shot for high-risk groups, paving way for the agency's OK

A key FDA advisory committee unanimously recommended Thursday giving booster shots of Moderna's Covid-19 vaccine to people ages 65 and older and other vulnerable Americans.

FDA panel unanimously recommends Moderna Covid booster shots for at risk adults

IDEXX Laboratories

Intuitive Surgical

Tesla's in the fast lane but these innovators could have more in the tank.

3 Healthcare Stocks That Are Better Than Tesla Right Now

The key advisory panel is set to vote Thursday on whether the agency should authorize a third dose of the Moderna vaccine.

Should Moderna's Booster Get Approval? FDA Advisory Committee Will Meet.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to report third quarter financial results on Thursday, November 4, 2021.

Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021

A booster could add to revenue down the road.

The FDA Is Set to Decide on Moderna's Booster. Here's What It Means for the Stock.

Johnson & Johnson

Pfizer

J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.

J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study Finds

The NIH study on “mixing and matching” Covid vaccines included more than 450 adults who have received one of the three regimens currently available in the United States: J&J's, Moderna's or Pfizer's.

J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggests

The FDA appears ready to approve its request for a COVID booster shot.

Why Moderna Stock Is Popping Today

Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022.

Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?

Pfizer is expanding beyond its coronavirus vaccine.

Can Pfizer Beat Moderna in mRNA Vaccines?

Some of the reasons behind the vaccine stock's sell-off appear to be much ado about nothing. But not all of them.

Is Moderna Stock a Buy After Plunging More Than 35%?

Food and Drug Administration staffers didn't take a firm stance on Moderna Inc.'s application for a booster dose, indicating there may not be sufficient data to support the extra dose.

The Wall Street Journal: FDA staff takes no position on Moderna's COVID booster

Moderna Inc (NASDAQ:MRNA) shares traded higher by 2% on Tuesday after U.S. Food and Drug Administration scientists opted not to take a stance on the company's COVID-19 vaccine booster shot. What Happened: In a new 45-page document, the FDA said data suggests two doses of the Moderna COVID-19 vaccine are enough to protect against the virus.

How To Play Moderna Stock Ahead Of Key FDA COVID-19 Booster Shot Ruling

Novavax

Ocugen, Inc.

Vaxart

Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnered with Bharat Biotech.

Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up

Costco

Delta Air Lines

FedEx

JPMorgan Chase & Co

NIKE

After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.

Pre-Markets Back to Green Ahead of Economic & Earnings Data

Food and Drug Administration staffers in an unusual move didn't take a stance on Moderna Inc.'s MRNA +0.72% application for a booster dose, indicating there may not be sufficient data to support the extra dose.

FDA Staff Don't Take Position on Moderna COVID-19 Booster

The U.S. Food and Drug Administration (FDA) will meet this week to debate whether or not extra doses of the Moderna, Inc. and Johnson & Johnson Janssen vaccines should be distributed, to whom and when.

FDA to meet over Moderna, Johnson & Johnson vaccine booster shots

Moderna Inc has signed to a deal to supply Covax with an additional 176.5mln doses of its coronavirus vaccine under an option deal agreed earlier. The US pharma has run into increasing criticism for its distribution policy amid accusations of targeting Europe, the US and other developed countries to maximise profits.

Moderna to supply Covax with 176.5mln doses for low income countries

Armada Hoffler Properties

Alico

American Tower

Alexandria Real Estate Equities

BRT Apartments

Camden Property

CatchMark Timber Trust

Farmland Partners

Gaming and Leisure Properties

Gladstone Commercial

Iron Mountain

Lexington Realty

MGM Growth Properties

Postal Realty Trust

Simon Property Group

STAG Industrial

UMH Properties

Uniti Group

Vici Properties

W. P. Carey

This high yield REIT portfolio is designed to outperform the market. We have hand selected the strongest individual stocks across a wide array of property types.

Our High Yield REIT Portfolio Heading Into The 4th Quarter

This is a critical step forward to winning formal clearance to be administered to people who received the first two doses.

FDA staff doesn't take stance on Moderna Covid booster shots, says two doses are enough to protect against severe disease

Shares of Moderna Inc. MRNA, +0.06% rallied 1.9% in premarket trading Tuesday, after the biotechnology company said Gavi, the Vaccine Alliance, has exercised its option to buy an additional 176.5 million COVID-19 vaccine doses for the Covax program. Of the additional doses, 116.5 million doses are expected to be delivered in the first quarter of 2022, while 60 million doses are expected to be delivered in the second quarter of 2022.

Moderna to deliver additional 176.5 million COVID-19 vaccine doses for Covax after options exercised

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces COVAX exercises option to purchase 176.5 million additional doses of Moderna's COVID-19 vaccine.

Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna's COVID-19 Vaccine for Low Income Countries in First Half of 2022

Committee members also will hear a presentation on a so-called mix-and-match booster, or a dose of a vaccine different from the original one.

FDA Advisory Panel Will Debate J&J and Moderna Boosters This Week

Moderna Inc (NASDAQ: MRNA) does not plan to share the formula for making its COVID-19 vaccine, Chairman Noubar Afeyan said in a recent interview with the Associated Press. What Happened: Afeyan told the Press that Moderna executives have come to the conclusion that ramping up production is the best way to address global supply.

News for Moderna Stock (MRNA)